Rallybio Corporation announced on February 17 2026 that its Phase 1 confirmatory pharmacokinetic/pharmacodynamic study of the Affibody‑based C5 inhibitor RLYB116 achieved complete and sustained inhibition of terminal complement at a 300 mg once‑weekly subcutaneous dose, with a safety profile consistent with other subcutaneous biologics.
The study, conducted in healthy volunteers, tested 150 mg and 300 mg once‑weekly doses. At 300 mg, the drug produced rapid onset and durable activity, and the most common adverse events were mild‑to‑moderate injection‑site reactions, confirming the tolerability of the subcutaneous route.
CEO Stephen Uden said the results were “highly encouraging” and reinforced the company’s belief that RLYB116 could be a best‑in‑class therapeutic. Chief Medical Officer Steven Ryder added that the data demonstrate the potential for rapid onset and sustained activity, offering clinical benefit and flexibility for a convenient dosing regimen that addresses unmet needs in immune platelet transfusion refractoriness, antiphospholipid syndrome and other complement‑mediated diseases.
Rallybio plans to initiate a Phase 2 proof‑of‑concept trial in immune platelet transfusion refractoriness in the second half of 2026, with topline results expected in 2027. The company’s reverse stock split, effective February 6 2026, was executed to meet Nasdaq’s minimum price requirement and does not affect the clinical development timeline.
The positive Phase 1 data strengthen Rallybio’s competitive position in the complement‑mediated disease space. A once‑weekly subcutaneous dosing schedule offers a potential advantage over existing monoclonal antibody therapies that require more frequent or intravenous administration, positioning RLYB116 as a convenient, best‑in‑class option for patients and clinicians.
The announcement underscores Rallybio’s progress toward bringing a novel therapeutic to market and signals confidence in the company’s Affibody platform, which has the potential to deliver small, high‑affinity proteins that can rival larger biologics in efficacy and patient convenience.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.